TIM-3 Expression Level on AML Blasts Correlates With Presence of Core Binding Factor Translocations Rather Than Clinical Outcomes.

TIM-3 acute myeloid leukemia core binding factor translocation flow cytometry prognosis

Journal

Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867

Informations de publication

Date de publication:
2022
Historique:
received: 19 02 2022
accepted: 18 03 2022
entrez: 2 5 2022
pubmed: 3 5 2022
medline: 3 5 2022
Statut: epublish

Résumé

T-cell immunoglobulin and mucin domain-containing molecule 3 (TIM-3) expresses on leukemic stem and progenitor populations of non-M3 acute myeloid leukemia (AML) as well as T lymphocytes. TIM-3 is thought to be involved in the self-renewal of leukemic stem cells and the immune escape of AML cells, however its correlation with AML prognosis is still controversial and worthy of further investigation. we simultaneously assessed TIM-3 expression levels of leukemic blasts and T lymphocytes in the bone marrow of TIM-3 expression of CD34 TIM-3 expression level on AML blasts correlates with presence of CBF translocations rather than clinical outcomes.

Sections du résumé

Background UNASSIGNED
T-cell immunoglobulin and mucin domain-containing molecule 3 (TIM-3) expresses on leukemic stem and progenitor populations of non-M3 acute myeloid leukemia (AML) as well as T lymphocytes. TIM-3 is thought to be involved in the self-renewal of leukemic stem cells and the immune escape of AML cells, however its correlation with AML prognosis is still controversial and worthy of further investigation.
Methods UNASSIGNED
we simultaneously assessed TIM-3 expression levels of leukemic blasts and T lymphocytes in the bone marrow of
Results UNASSIGNED
TIM-3 expression of CD34
Conclusion UNASSIGNED
TIM-3 expression level on AML blasts correlates with presence of CBF translocations rather than clinical outcomes.

Identifiants

pubmed: 35494006
doi: 10.3389/fonc.2022.879471
pmc: PMC9046698
doi:

Types de publication

Journal Article

Langues

eng

Pagination

879471

Informations de copyright

Copyright © 2022 Hong, Xia, Huang, Yuan, Liang, Dai, Wu, Liang, Ruan, Long, Cheng, Chen, Ni, Ge, Li, Zeng, Xia, Wang and Yang.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

Int Immunopharmacol. 2015 Dec;29(2):635-641
pubmed: 26428847
Clin Cancer Res. 2018 Sep 1;24(17):4175-4186
pubmed: 29437767
Int J Clin Exp Pathol. 2014 Sep 15;7(10):6880-8
pubmed: 25400771
Expert Rev Anticancer Ther. 2021 May;21(5):523-534
pubmed: 33334180
Science. 2007 Nov 16;318(5853):1141-3
pubmed: 18006747
Leukemia. 2020 Oct;34(10):2607-2620
pubmed: 32203137
Nat Immunol. 2005 Dec;6(12):1245-52
pubmed: 16286920
Cancer Discov. 2012 May;2(5):401-4
pubmed: 22588877
Leuk Lymphoma. 2022 Jan;63(1):152-161
pubmed: 34405769
Cell Stem Cell. 2015 Sep 3;17(3):341-52
pubmed: 26279267
Oncol Lett. 2021 Apr;21(4):325
pubmed: 33692857
Nat Rev Immunol. 2020 Mar;20(3):173-185
pubmed: 31676858
Sci Signal. 2013 Apr 02;6(269):pl1
pubmed: 23550210
Proc Natl Acad Sci U S A. 2011 Mar 22;108(12):5009-14
pubmed: 21383193
Blood. 2011 Apr 28;117(17):4501-10
pubmed: 21385853
Asia Pac J Clin Oncol. 2020 Jun;16(3):137-141
pubmed: 32030888
Cancer Lett. 2021 Jul 10;510:67-78
pubmed: 33895262
N Engl J Med. 2013 May 30;368(22):2059-74
pubmed: 23634996
J Immunother Cancer. 2020 Jun;8(1):
pubmed: 32601081
Cell Mol Immunol. 2018 Nov;15(11):989-991
pubmed: 29872115
Oncotarget. 2016 Sep 6;7(36):57811-57820
pubmed: 27506934
Semin Oncol. 2008 Aug;35(4):410-7
pubmed: 18692691
Cancer Cell. 2018 Jan 8;33(1):60-74.e6
pubmed: 29316433
Semin Immunol. 2019 Apr;42:101302
pubmed: 31604535
Oncotarget. 2017 Oct 27;8(60):102088-102096
pubmed: 29254227
Nature. 2002 Jan 31;415(6871):536-41
pubmed: 11823861
PLoS One. 2012;7(2):e30676
pubmed: 22363469
J Exp Med. 2010 Sep 27;207(10):2187-94
pubmed: 20819927
Blood. 2000 Dec 15;96(13):4075-83
pubmed: 11110676
EBioMedicine. 2017 Aug;22:44-57
pubmed: 28750861
J Exp Med. 2015 Dec 14;212(13):2289-304
pubmed: 26598760
Cell Stem Cell. 2010 Dec 3;7(6):708-17
pubmed: 21112565

Auteurs

Jian Hong (J)

Department of Hematology, The First Affiliated Hospital of Anhui Medical University, Hefei, China.

Leiming Xia (L)

Department of Hematology, The Forth Affiliated Hospital of Anhui Medical University, Hefei, China.

Zhenqi Huang (Z)

Department of Hematology, The First Affiliated Hospital of Anhui Medical University, Hefei, China.

Xiaodong Yuan (X)

Division of Life Sciences and Medicine, Department of Organ Transplantation Center, Transplant and Immunology Laboratory, The First Affiliated Hospital of University of Science and Technology of China (USTC), University of Science and Technology of China, Hefei, China.

Xinglin Liang (X)

Department of Hematology, The First Affiliated Hospital of Anhui Medical University, Hefei, China.

Jifei Dai (J)

Department of Hematology, The First Affiliated Hospital of Anhui Medical University, Hefei, China.

Zhonghui Wu (Z)

Department of Hematology, The First Affiliated Hospital of Anhui Medical University, Hefei, China.

Li Liang (L)

Department of Hematology, The First Affiliated Hospital of Anhui Medical University, Hefei, China.

Min Ruan (M)

Department of Hematology, The First Affiliated Hospital of Anhui Medical University, Hefei, China.

Zhangbiao Long (Z)

Department of Hematology, The First Affiliated Hospital of Anhui Medical University, Hefei, China.

Xin Cheng (X)

Department of Hematology, The First Affiliated Hospital of Anhui Medical University, Hefei, China.

Xiaowen Chen (X)

Department of Hematology, The First Affiliated Hospital of Anhui Medical University, Hefei, China.

Jing Ni (J)

Department of Hematology, The First Affiliated Hospital of Anhui Medical University, Hefei, China.

Jian Ge (J)

Department of Hematology, The First Affiliated Hospital of Anhui Medical University, Hefei, China.

Qingsheng Li (Q)

Department of Hematology, The First Affiliated Hospital of Anhui Medical University, Hefei, China.

Qingshu Zeng (Q)

Department of Hematology, The First Affiliated Hospital of Anhui Medical University, Hefei, China.

Ruixiang Xia (R)

Department of Hematology, The First Affiliated Hospital of Anhui Medical University, Hefei, China.

Yi Wang (Y)

Department of Oncology, The Third Affiliated Hospital of Anhui Medical University, Hefei, China.

Mingzhen Yang (M)

Department of Hematology, The First Affiliated Hospital of Anhui Medical University, Hefei, China.
Department of Hematology, The Forth Affiliated Hospital of Anhui Medical University, Hefei, China.

Classifications MeSH